Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

Todd Neale

December 08, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

News Daily News

Heart Failure Risks of Smoking Can Linger for Decades

L.A. McKeown

June 07, 2022

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

Shelley Wood

May 22, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Daily News

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

Todd Neale

April 20, 2022

News Daily News

Infertility in Women Linked to Subsequent Risk of HFpEF

L.A. McKeown

April 19, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Todd Neale

January 21, 2022

Advertisement

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

Heart Failure Risks of Smoking Can Linger for Decades

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

Infertility in Women Linked to Subsequent Risk of HFpEF

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

Guideline-Directed Therapies Underused in Frail HF Patients

FDA Approves Empagliflozin for Treatment of HFpEF

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content